Managing Cardiovascular Risk as Part of Comprehensive Psoriatic Arthritis Care

Key Takeaways:

• Cardiovascular risk is a core component of PsA care, not a side issue. Patients carry roughly 43 percent higher cardiovascular risk than the general population, much of it inflammation-driven and clinically silent.
• Standard risk calculators underestimate the danger. Tools like Framingham and SCORE2 misclassify PsA patients, so interpret them conservatively and add vascular imaging in higher-risk cases.
• PsA treatment is itself a cardiovascular lever. Controlling inflammation lowers risk – methotrexate and TNF inhibitors look most favorable – while glucocorticoids and JAK inhibitors warrant caution.

Psoriatic arthritis (PsA) is too often framed as a disease of the joints, entheses, and skin. Yet for the clinician thinking decades ahead for a patient, the most consequential organ in the room may be the one that never appears on a swollen-joint count.

PsA is a systemic immune-mediated disease that carries a substantial, independent excess of major adverse cardiovascular events (MACE), and cardiovascular disease (CVD) is a leading contributor to the premature mortality observed in this population.¹

The scope of the excess risk

The magnitude is not trivial. Synthesized epidemiologic data indicate that patients with PsA carry roughly a 43 percent higher overall cardiovascular risk and a 55 percent higher incidence of CVD than the general population, with disproportionate increases in heart failure, cerebrovascular disease, and myocardial infarction.¹

Critically, this excess persists after adjustment for traditional risk factors, pointing to disease-specific mechanisms – cytokine-driven endothelial dysfunction, a pro-thrombotic milieu, accelerated atherogenesis, and cardiometabolic clustering (metabolic syndrome, obesity, insulin resistance, dyslipidemia).¹

The vascular burden is frequently silent: Carotid ultrasound studies consistently demonstrate greater intima-media thickness and a markedly higher prevalence of carotid plaque, and inflammatory burden tracks with this subclinical atherosclerosis. In other words, the patient with well-controlled skin and joints may still be accumulating arterial disease.^1,2

Why standard risk calculators fall short

General-population algorithms – Framingham, SCORE2, ASCVD, QRISK – were not derived in inflammatory cohorts and tend to misclassify PsA patients, often leaving future event-positive individuals in the low- or intermediate-risk categories.¹

The inflammatory "1.5 multiplier" borrowed from rheumatoid arthritis has not improved calibration in PsA cohorts, and current EULAR guidance endorses it for RA but not for PsA. Until disease-specific models are validated, conventional scores should be interpreted conservatively, particularly in long-standing, active, or severe disease, and supplemented selectively with vascular imaging (carotid ultrasound or coronary artery calcium scoring) in patients with multiple risk factors or high cumulative inflammatory exposure.^1,3,4

Treatment of PsA as a cardiovascular lever

A distinctive feature of PsA care is that disease-directed therapy itself modifies cardiovascular trajectory – in both directions. Effective suppression of systemic inflammation is, in effect, a cardiovascular intervention. Methotrexate and TNF inhibitors carry the most consistent signals toward lower MACE, and population-based data suggest TNF-α, IL-17, and IL-23 inhibitors are associated with reduced CVD event rates relative to conventional systemic therapy.^1,5

Conversely, some agents demand caution: Systemic glucocorticoids show a dose- and duration-dependent increase in cardiovascular events, and JAK inhibitors warrant careful consideration in patients with established atherosclerotic disease or multiple risk factors. Cardiovascular profile, therefore, belongs alongside articular and cutaneous efficacy when selecting and sequencing therapy.³

An integrated cardio-rheumatology model

Translating this evidence into care requires a deliberate, coordinated approach rather than fragmented hand-offs between specialties. Several practical commitments define it. First, systematic screening at the point of PsA diagnosis: blood pressure, a full lipid profile, fasting glucose or HbA1c, body mass index and waist circumference, and smoking status, with periodic reassessment. Comorbidity guidance from GRAPPA likewise positions baseline CVD and high cardiovascular risk as factors that should actively shape treatment choice.^4,6

Second, harmonized treat-to-target goals, in which achieving low disease activity or remission (by DAPSA or PASDAS) and meeting guideline-directed lipid, blood pressure, and glycemic targets are treated as parallel, co-primary priorities.¹

Third, structured lifestyle intervention – even modest, intentional weight loss of around 5 percent improves treatment responsiveness and the likelihood of minimal disease activity in overweight patients.¹

Finally, proactive pharmacologic prevention: statins and renin-angiotensin system blockers as the foundation, with SGLT2 inhibitors and GLP-1 receptor agonists increasingly compelling in PsA patients with obesity, diabetes, or markedly elevated global risk.¹

The move toward comprehensive care

Comprehensive PsA care means looking past the joint count. The increased cardiovascular risk is real, partly inflammation-driven, frequently subclinical, and poorly captured by standard calculators – but it is also modifiable.

By screening systematically at diagnosis, choosing therapy with the cardiovascular profile in mind, controlling inflammation, and partnering with cardiology and primary care around shared targets, clinicians can meaningfully reduce the MACE burden their PsA patients would otherwise carry. Treating the inflammation and protecting the heart are not competing aims; in PsA, they are the same task.